Why did Synthetic Biologics plummet?
Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, lost more than 16 percent and hit a new 52-week low of $1.17 on Tuesday after the company released results of an independent third party evaluation of its Phase 2 clinical trial.
Is Synthetic Biologics a good buy?
Synthetic Biologics Inc (SYN) stock is down -10.53% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives SYN stock a score of 79 out of a possible 100.
What does Synthetic Biologics Inc do?
Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.
Is syn stock a good buy?
There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Synthetic Biologics stock.
What does SYN company do?
Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.